Shanna Babalonis Selected Research

Miosis

9/2021	Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans - pilot study outcomes.
11/2019	Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans.
5/2016	Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
1/2016	Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.
12/2015	Safety of oral dronabinol during opioid withdrawal in humans.
11/2013	Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shanna Babalonis Research Topics

Disease

6	Miosis 09/2021 - 11/2013
5	Pain (Aches) 01/2021 - 01/2016
5	Opioid-Related Disorders (Opiate Addiction) 01/2020 - 11/2013
3	Substance-Related Disorders (Drug Abuse) 01/2021 - 06/2011
2	Respiratory Insufficiency (Respiratory Failure) 09/2021 - 01/2016
1	Mental Disorders (Mental Disorder) 01/2021
1	Nervous System Diseases (Neurological Disorders) 01/2021
1	Inflammation (Inflammations) 01/2021
1	Tobacco Use Disorder (Nicotine Dependence) 01/2020
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2020
1	Chronic Pain 01/2020
1	Marijuana Abuse (Cannabis Abuse) 11/2018
1	Neoplasms (Cancer) 03/2017
1	Epilepsy (Aura) 03/2017
1	Opium Dependence 01/2017
1	Acute Pain 01/2017
1	Tachycardia (Tachyarrhythmias) 07/2016
1	Sinus Tachycardia 12/2015
1	Rhinorrhea 11/2013
1	Sneezing 11/2013
1	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2013
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 06/2011

Drug/Important Bio-Agent (IBA)

9	Opioid Analgesics (Opioids)IBA 09/2021 - 11/2013
4	Analgesics (Analgesic Drugs)IBA 01/2020 - 01/2016
3	Pharmaceutical PreparationsIBA 09/2021 - 03/2017
3	Oxycodone (Oxycontin)FDA LinkGeneric 11/2019 - 12/2015
3	Dronabinol (THC)FDA LinkGeneric 11/2019 - 12/2015
2	Oxymorphone (Numorphan)FDA LinkGeneric 09/2021 - 01/2016
2	Therapeutic UsesIBA 01/2021 - 03/2017
2	CannabinoidsIBA 01/2020 - 07/2016
1	Nicotine FDA Link 01/2020
1	AticaprantIBA 01/2020
1	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2020
1	Cannabinoid Receptor AgonistsIBA 11/2019
1	Acetylcysteine (Siran)FDA LinkGeneric 11/2018
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 07/2016
1	mu Opioid Receptors (mu Opioid Receptor)IBA 12/2015
1	Tramadol (K315)FDA LinkGeneric 11/2013
1	Hormones (Hormone)IBA 06/2011
1	Biological FactorsIBA 06/2011
1	Dextroamphetamine (Dexedrine)FDA LinkGeneric 06/2011

Therapy/Procedure

1	Self Administration (Administration, Self) 01/2020
1	Analgesia 11/2019
1	Drug Tapering 12/2015